Boston Scientific shares fell 3.2% in pre-market trading to $48.25 after the company disclosed a cybersecurity incident that disrupted global operations and limited order fulfillment.
The incident, which occurred on August 25, prompted the activation of incident response protocols and the engagement of third-party cybersecurity specialists. The company’s stock has traded between $42.20 and $109.50 over the past 52 weeks.
Analysts have adjusted their outlooks following the disruption and subsequent guidance revisions. TD Cowen reiterated a buy rating but reduced its price target to $56, citing recent guidance cuts and cautious management commentary that drove estimate reductions through 2027. Consensus revenue growth forecasts for 2027 were lowered to 4%, down from 8% prior to the second-quarter earnings report.
Argus downgraded Boston Scientific to hold, citing headwinds in the WATCHMAN and electrophysiology product lines. The broader U.S. equity market showed minimal movement, with the S&P 500 down 0.1% and the Nasdaq down 0.2%.
